BRIEF-Monte Rosa Therapeutics Announces Global License Pact With Novartis To Advance T And B Cell-Modulating Vav1-Directed Molecular Glue Degraders

Reuters
28 Oct 2024

Oct 28 (Reuters) - Monte Rosa Therapeutics Inc :

* MONTE ROSA THERAPEUTICS: GLOBAL LICENSE PACT WITH NOVARTIS TO ADVANCE T AND B CELL-MODULATING VAV1-DIRECTED MOLECULAR GLUE DEGRADERS

* MONTE ROSA THERAPEUTICS: CO TO GET UP-FRONT PAYMENT OF $150 MILLION & ELIGIBLE TO GET MILESTONE PAYMENTS

* MONTE ROSA THERAPEUTICS: NOVARTIS TO OBTAIN WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE & COMMERCIALIZE MRT-6160 AND OTHER VAV1 MGDS

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10